Keywords: South Korea, Type 2 diabetes, Market forecasts, Merck & Co, Januvia, Janumet, Novo Nordisk, Victoza, Amylin, Bydureon, Decision Resources
South Korea's type 2 diabetes drug market to grow to over $550 million in 2016
Article | 23 October 2012
The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011 to more than $550 million in 2016, according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
